Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)

 Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in Patients with Atypical Hemolytic Uremic Syndrome (AHUS)

Shots:

  • The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS, receiving dose based on their weight varying upto 3,600 mg for 2 years
  • P-III study results: reduction in thrombocytopenia in 83.9% patients; reduction in hemolysis in 76.8% patients; improved kidney function in 58.9% patients; No case of meningococcal infection observed; safe results
  • Ultomiris (ravulizumab-cwvz) is a mAb and has received ODD from the US and EU for Paroxysmal Nocturnal Hemoglobinuria (PNH) in adults and aHUS in SC respectively

Click here to read full press release/ article | Ref: Alexion | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post